Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has approved Watson’s Rosuvastatin Calcium Tablets, the first generic version of AstraZeneca‘s Crestor.
Crestor is indicated for use in combination with diet for the treatment of hypertriglyceridemia in adults; in combination with diet for the treatment of primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia); and either alone or in combination with other cholesterol treatment(s) for adults with homozygous familial hypercholesterolemia.
Rosuvastatin is an HMG-CoA reductase inhibitor that works by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL, and also inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
For more information call (888) 463-6332 or visit FDA.gov.
